BioCryst Pharmaceuticals, Inc. (BCRX) earnings
BCRX earnings moved a median of -0.45% by the close. Quarterly and annual BCRX reports and results, each read against the price at its own news timestamp. Back to the BCRX overview →
33 measured BCRX earnings events.
Where these BCRX earnings landedvs 33 measured BCRX earnings reactions
| Middle 50% of BCRX earnings reactions | -3.11% to +3.06% |
|---|---|
| Median reaction (to close) | -0.45% |
| Measured reactions | 33 |
Point-in-time · zero look-ahead
Half of the 33 BCRX earnings events with a measured close landed between -3.11% and +3.06%; 48% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| BioCryst Reports Second Quarter 2026 Financial Results | Press release | +1.22% | -3.92% | |
| Form 10-Q BIOCRYST PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +2.88% | |
| BioCryst to Report Second Quarter 2026 Financial Results on August 5 | Press release | +1.17% | +1.49% | |
| BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | -6.72% | +3.88% | |
| Form 10-Q BIOCRYST PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | -1.36% | +1.14% | |
| BioCryst to Report First Quarter 2026 Financial Results on May 6 | Press release | -1.69% | -3.18% | |
| Form 10-K BIOCRYST PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | +4.78% | +10.06% | |
| BioCryst to Report Fourth Quarter 2025 Financial Results on February 26 | Press release | +0.78% | -3.11% | |
| Form 10-Q BIOCRYST PHARMACEUTICALS For: Sep 30 | SEC filing · Form 10-Q | +2.62% | +4.52% | |
| BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | +0.70% | -3.92% | |
| BioCryst to Report Third Quarter 2025 Financial Results on November 3 | Press release | -0.15% | +3.90% | |
| Form 10-Q BIOCRYST PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | -0.12% | +2.75% | |
| BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | -8.86% | -4.49% | |
| BioCryst to Report Second Quarter 2025 Financial Results on August 4 | Press release | +0.00% | -1.27% | |
| Form 10-Q BIOCRYST PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | +0.53% | -2.80% | |
| BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | +2.00% | +13.01% | |
| BioCryst to Report First Quarter 2025 Financial Results on May 5 | Press release | -0.82% | +2.87% | |
| Form 10-K BIOCRYST PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | -1.26% | +0.48% | |
| BioCryst to Report Fourth Quarter 2024 Financial Results on February 24 | Press release | -0.47% | -0.69% | |
| Form 10-Q BIOCRYST PHARMACEUTICALS For: Sep 30 | SEC filing · Form 10-Q | +1.39% | +7.51% | |
| BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update | Press release | -3.73% | -5.41% | |
| BioCryst to Report Third Quarter 2024 Financial Results on November 4 | Press release | -0.13% | -0.79% | |
| Form 10-Q BIOCRYST PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | -1.00% | -7.00% | |
| BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update | Press release | +8.21% | +15.72% | |
| BioCryst to Report Second Quarter 2024 Financial Results on August 5 | Press release | +1.25% | +3.06% | |
| Form 10-Q BIOCRYST PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | -0.48% | -1.54% | |
| BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update | Press release | +0.80% | +5.40% | |
| BioCryst to Report First Quarter 2024 Financial Results on May 6 | Press release | +0.23% | -0.45% | |
| Form 10-K BIOCRYST PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | +1.56% | -1.04% | |
| BioCryst to Report Fourth Quarter 2023 Financial Results on February 26 | Press release | +3.99% | +1.02% | |
| Form 10-Q BIOCRYST PHARMACEUTICALS For: Sep 30 | SEC filing · Form 10-Q | -1.54% | -8.91% | |
| BioCryst Reports Third Quarter 2023 Financial Results and Provides Business Update | Press release | -6.59% | -4.73% | |
| BioCryst to Report Third Quarter 2023 Financial Results on November 2 | Press release | -1.90% | -1.38% |
Keep exploring
More BCRX: analyst actions → · SEC filings → · BCRX overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| CORIUM INTL (CORI) | 380 | 0.00% | 46% |
| PROTEON THERAPEUTICS (PRTO) | 380 | 0.00% | 39% |
| Constellation Pharmaceuticals, Inc (CNST) | 379 | 0.00% | 44% |
| CONTRAVIR PHARMACEUTICALS INC (CTRV) | 379 | -0.51% | 36% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.